- argenx SE at Barclays Global Healthcare Conference TranscriptMar 12, 2024
- Q4 2023 argenx SE Earnings Call TranscriptFeb 29, 2024R$82.4Earnings
- argenx SE at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus TranscriptDec 20, 2023
- argenx SE Investor Call TranscriptNov 28, 2023
- Q3 2023 argenx SE Earnings Call TranscriptOct 31, 2023R$100.08Earnings
- argenx SE at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- argenx SE at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 argenx SE Earnings Call TranscriptJul 27, 2023R$81.75Earnings
- argenx SE To Discuss the Adhere Results TranscriptJul 17, 2023
- argenx SE To Discuss Drug Administration Approval of VYVGART TranscriptJun 21, 2023
- argenx SE at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 argenx SE Earnings Call TranscriptMay 04, 2023R$79.5Earnings
- argenx SE at TD Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 argenx SE Earnings Call TranscriptMar 02, 2023R$79.5Earnings
- argenx SE Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM TranscriptJan 09, 2023
- argenx SE at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- argenx SE at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Q3 2022 argenx SE Earnings Call TranscriptOct 27, 2022R$77.1 (-5.05%)Earnings
- Q2 2022 argenx SE Earnings Call TranscriptJul 28, 2022R$78.24Earnings
- argenx SE at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- argenx SE at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 argenx SE Earnings Call TranscriptMay 05, 2022R$59.89Earnings
- argenx SE Topline Phase 3 Data From ADAPT-SC Study Call TranscriptMar 22, 2022
- argenx SE at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Q4 2021 argenx SE Earnings Call TranscriptMar 03, 2022R$57.35Earnings
- argenx SE at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- argenx SE To Discuss FDA Approval Call TranscriptDec 17, 2021
- Q3 2021 argenx SE Earnings Call TranscriptOct 28, 2021R$64.48Earnings
- argenx SE at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 argenx SE Earnings Call TranscriptJul 29, 2021R$60.8Earnings
- argenx SE virtual R&D Day Call TranscriptJul 20, 2021
- argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 argenx SE Earnings Call TranscriptMay 14, 2021R$55.05Earnings
- argenx SE Presents At Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Full Year 2020 argenx SE Earnings Call TranscriptMar 04, 2021R$66.63 (-9.16%)Earnings
- argenx SE - Special Call TranscriptFeb 01, 2021
- argenx SE at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- argenx SE at Stifel Virtual Healthcare Conference TranscriptNov 17, 2020
- Q3 2020 argenx SE Earnings Call TranscriptOct 22, 2020R$56.61 (-2.90%)Earnings
- argenx SE at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- argenx SE at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Half Year 2020 argenx SE Earnings Call TranscriptJul 30, 2020Earnings
- argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- argenx SE Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis - Call TranscriptMay 26, 2020
- Q1 2020 argenx SE Earnings and Business Update Call TranscriptMay 14, 2020
- argenx SE at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 12, 2020
- Q4 2019 argenx SE Earnings Call TranscriptFeb 27, 2020Earnings
- argenx SE at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- argenx SE at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 argenx SE Earnings Call TranscriptAug 01, 2019Earnings
- argenx SE - Special Call TranscriptMay 22, 2019
- Q4 2018 argenx SE Earnings Call TranscriptFeb 28, 2019Earnings
argenx SE at JPMorgan Healthcare Conference Transcript
Great. Good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, I've got the pleasure of introducing the Argenx presentation. We're going to have a breakout afterwards in the Sussex room, and I can help lead you there. But with that said, I'll hand over to Tim Van Hauwermeiren for the presentation. Thank you very much.
Thank you, James. Good afternoon, ladies and gentlemen. My promise to you for the next 25 minutes is that we are going to take a close look at our patient focus. We're going to take a look at MyRealWorld MG, our real world evidence study in myasthenia gravis. We're also going to learn how we have been adapting the design of our Phase III global registration trial to the will of the MG patients. We're also going to take a closer look at the late-stage clinical development pipeline of the company.
We're going to take a closer look at efgartigimod and cusatuzumab,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)